← Back

Wire · opportunities

Five labs fail to replicate therapeutic effects of psilocybin in mice

Published

14 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at drugdiscoverynews.com →

◆ Verified

Fusion42 · 14 November 2026 · Fusion42 review

Five different research labs conducted a joint study using identical protocols and found that psilocybin failed to produce replicable long-lasting therapeutic effects on anxiety or depression in mice, though it did reduce fear expression and increase acute anxiety. This raises questions about the reliability of preclinical animal behavior experiments underpinning psychedelic therapeutic claims.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must now question preclinical behavioural data in psychedelic therapy development as this study reveals key effects are not reliably replicable in mice. Expect funders and partners to demand more robust foundational data before backing your psilocybin programmes.

◆ Coverage

1 source · 14 Nov 2026

◆ Related on Wire

◆ Topics

Biotechpsilocybinpsychedelic-therapyreplication-crisisanimal-modelsbiotech-research